<DOC>
	<DOCNO>NCT01968668</DOCNO>
	<brief_summary>This study conduct Japanese subject type 2 diabetes mellitus clinical diagnosis Diabetic Nephropathy ( DN ) use multi-center , randomize , adaptive , double-blind , placebo-controlled , parallel-group design . Primary objective study investigate change Urinary Albumin Creatine Ratio ( UACR ) treatment different oral dos BAY94-8862 give daily baseline Visit 8 ( Day 90 )</brief_summary>
	<brief_title>Safety Efficacy Different Oral Doses BAY94-8862 Japanese Subjects With Type 2 Diabetes Mellitus Clinical Diagnosis Diabetic Nephropathy ( ARTS-DN Japan )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Diabetic Nephropathies</mesh_term>
	<criteria>Japanese subject type 2 diabetes mellitus clinical diagnosis DN ( Diabetic Nephropathy ) treat least minimal recommend dose Angiotensin Converting Enzyme Inhibitor ( ACEI ) and/or Angiotensin Receptor Blocker ( ARB ) Subjects clinical diagnosis Diabetic Nephropathy ( DN ) base least 1 follow criterion : Persistent high albuminuria define Urinary Albumin Creatine Ratio ( UACR ) &gt; /=300 mg/g ( &gt; /=34 mg/mmol ) 2 3 first morning void sample estimate glomerular filtration rate ( eGFR ) &gt; /=30 mL/min/1.73 m2 &lt; 90 mL/min/1.73 m2 Chronic Kidney DiseaseEpidemiology Collaboration ( CKDEPI ) Persistent high albuminuria define UACR &gt; /=30 mg/g &lt; 300 mg/g ( &gt; /=3.4 mg/mmol &lt; 34 mg/mmol ) 2 3 first morning void sample eGFR &gt; /=30 mL/min/1.73 m2 &lt; 90 mL/min/1.73 m2 ( CKDEPI ) Serum potassium &lt; /=4.8 mmol/L runin visit screen visit Nondiabetic renal disease ( confirm biopsy ) Known bilateral clinically relevant renal artery stenosis ( &gt; 75 % ) Glycated hemoglobin ( HbA1c ) &gt; 12 % runin visit screen visit UACR &gt; 3000 mg/g ( 339 mg/mmol ) urinary first morning void sample runin visit screen visit Hypertension mean sit systolic blood pressure ( SBP ) &gt; /=180 mmHg mean sit diastolic blood pressure ( DBP ) &gt; /=110 mmHg runin visit mean sit SBP &gt; /=160 mmHg mean sit DBP &gt; /=100 mmHg screen visit Subjects clinical diagnosis heart failure reduce ejection fraction ( HFrEF ) persistent symptom ( New York Heart Association class IIIV ) runin visit Concomitant therapy eplerenone , spironolactone , renin inhibitor , potassiumsparing diuretic</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>BAY94-8862</keyword>
	<keyword>MR antagonist</keyword>
	<keyword>Diabetic nephropathy</keyword>
	<keyword>Japanese patient</keyword>
</DOC>